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Available online 26 November 2015The Genea047 human embryonic stem cell line was derived from a donated, fully commercially consented
ART blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell
morphology and genomic analysis veriﬁed a 46, XX karyotype and female allele pattern through traditional
karyotyping, CGH and STR analysis. Pluripotency of Genea047 was demonstrated with 88% of cells express-
ing Nanog, 95% Oct4, 59% Tra1-60 and 99% SSEA4, a PluriTest Pluripotency score of 30.86, Novelty score of
1.23 and tri-lineage teratoma formation. The cell line was negative for Mycoplasma and any visible
contamination.
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Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and both
ICM and trophectoderm were plated onto mitomycin C inactivated De-
troit 551 HFF human feeders (plated 90,000 cells 1 well of 4 well —
47,368 cells/cm2) in 20% Knock out serum in standard hESC cultureme-
dium (Amit et al., 2000) with 20 ng/mL Fgf2. CGH, karyotyping and STR
proﬁling were performed at the ﬁrst cryobanking step from ICM out-
growthsmaintained on feeders. Alkaline phosphatase stainingwas per-
formed on feeders. Cells were then enzymatically passaged as single
cells in M2 pluripotent cell maintenance medium (Genea Biocells) and
genetic analysis repeated, immunoﬂuorescent pluripotent marker
staining, PluriTest, teratoma and sterility testing performed.ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Brightﬁeld morphology of Genea047 on human inactivated feeders.
Table 1
CGH array summary.
Parameter Result
Sample name Genea047p8_2
Date reported 14th August 2013
Hybridisation
balance
A balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number
change
No copy number changes N400 kb were detected
Interpretation Female cell line — no abnormalities detected
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1. Karyotyping: Passage 5; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/mL BrdU (Sigma) for 17–19 h or 5 ng/mL
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory for
preparation of metaphase spreads and cytogenetic analysis by G-
banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts was performed for 5
and 10 of the metaphases respectively.
2. Comparative genomic hybridisation (CGH) based chromosomal
analysis: Passage 8 (6 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarraysFig. 2. Kary(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).
3. DNA Proﬁling: Passage 4; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
Pluripotency assessment
1. Immunoﬂuorescence: Passage 8 (6 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen:). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. PluriTest: Passage 9 (6 on feeders, 3 enzymatic); RNA was collected
and subjected to a PluriTest, a bioinformatic assay of pluripotency
in human cells based on gene expression proﬁles (Müller et al., 2012)
3. Teratoma formation: Passage 8; Stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20% KSR for in-
jection. In both experiments, mice were anaesthetized before intra-
muscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1xT25) in 50 μL were
injected per mouse at one site only. Resultant teratomas wereotype.
Fig. 3. STR proﬁle.
Fig. 4. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by immunoﬂuorescence.
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Fig. 5. PluriTest.
Fig. 6. Identiﬁcation of tri-lineage teratoma differentiation.
325B. Dumevska et al. / Stem Cell Research 16 (2016) 322–326excised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 4; testingwas performed at the Victorian Infec-
tious Diseases Reference Laboratory usingMycoplasma Genus PCR
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consentform can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea047 has been derived from
a donated, fully commercially consented human embryo, originally cre-
ated by assisted reproduction technology (ART) for the purpose of pro-
creation, under Australian National Health and Medical Research
Council (NHMRC) licence 309703. This licence was issued to GENEA
on 16 April 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-
use-excess-art-embryos.
Morphology
The derived stem cell line, Genea047, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1).
Genetic analysis
The cell line has been karyotyped (Fig. 2, Supplementary Fig. 1) and
tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46,
XX karyotype, consistent with original derivation. Analysis of STR
markers showed Allele pattern consistent with female genotype (Fig.
3, Supplementary Fig. 3).
Disease status
Unaffected.
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GENEA047 is pluripotent by;
1. Immunoﬂuorescence with 88% Nanog positive, 95% Oct4 positive,
59% Tra1-60 positive, and 99% SSEA4 positive (Fig. 4A, quantiﬁed in
4B).
2. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 5).
3. PluriTest with a 30.86 Pluripotency score and 1.23 Novelty score
(Fig. 6).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.012.
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